$SDMHF

Sartorius Stedim Biotech S.A./ADR

Sartorius Stedim Biotech supplies equipment, materials and services for biopharmaceutical production and research. Its offerings include cell culture products, bioreactors, separation and purification systems, storage and transport solutions, testing instruments, sensors, analytical tools, software and process automation. The company also provides fluid management, water purification and weighing products. It serves drug, vaccine, food and chemical manufacturers, along with research and development laboratories, and is based in Aubagne, France.

No enriched coverage for $SDMHF in the last 7 days.

No SEC Form 4 filings for $SDMHF in the last 30 days.

See all $SDMHF insider activity →

Sartorius Stedim Biotech: Buy rating from Goldman Sachs

Goldman Sachs assigned a Buy rating to Sartorius Stedim Biotech, following a similar rating from Barclays. The rating is based on a weighted average of various metrics, including valuation and EPS revisions. The company's stock is currently trading at 212.00 EUR on Euronext Paris.

Sartorius Stedim Biotech: From Neutral to Buy by UBS

UBS upgraded Sartorius Stedim Biotech from Neutral to Buy, citing a weighted average of ratings including valuation, EPS revisions, and visibility. The company's stock is currently at 192.20 EUR, up 5.08% over 5 days and 6.13% year-to-date.

SDMHF sentiment & insider activity

Recent SDMHF coverage spans earnings, financial news and market movers.

What's driving SDMHF

  • Sartorius Stedim Biotech SA reported 9M 2026 sales of €2.289B, a 6.5% increase, with an EBITDA margin of 31.3% and net profit of €277M. Free cash flow rose to €264M, and the company maintained its full-year guidance, refining its capex ratio to ~13%.

    tradingview.com · Oct 22, 2026

  • Goldman Sachs assigned a Buy rating to Sartorius Stedim Biotech, following a similar rating from Barclays. The rating is based on a weighted average of various metrics, including valuation and EPS revisions. The company's stock is currently trading at 212.00 EUR on Euronext Paris.

    marketscreener.com · Oct 1, 2026

  • UBS upgraded Sartorius Stedim Biotech from Neutral to Buy, citing a weighted average of ratings including valuation, EPS revisions, and visibility. The company's stock is currently at 192.20 EUR, up 5.08% over 5 days and 6.13% year-to-date.

    marketscreener.com · Aug 20, 2026

  • Sartorius Stedim Biotech (STDM) stock rose 5.0% to €192.1 after UBS upgraded its rating to Buy and raised its price target to €260 from €220. UBS cited strong demand for bioprocess consumables and anticipated biosimilar launches. The upgrade also boosted parent company Sartorius AG. The move was driven by company-specific news, not broader market trends.

    investing.com · Aug 20, 2026

  • UBS upgraded Sartorius Stedim Biotech to buy, raising its price target to €260 from €220. JP Morgan upgraded Michelin to overweight, increasing its target to €42 from €35. JP Morgan also trimmed Elis's target to €28.20, while UBS raised Getlink's to €19.80.

    marketscreener.com · Aug 20, 2026

AlphAI scores every news story that mentions SDMHF with an AI model for sentiment and relevance, and aggregates insider trades from Sartorius Stedim Biotech S.A./ADR's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SDMHF

Score

Why is Sartorius Stedim Biotech stock surging today?

Sartorius Stedim Biotech (STDM) stock rose 5.0% to €192.1 after UBS upgraded its rating to Buy and raised its price target to €260 from €220. UBS cited strong demand for bioprocess consumables and anticipated biosimilar launches. The upgrade also boosted parent company Sartorius AG. The move was driven by company-specific news, not broader market trends.

Sartorius Stedim Biotech SA: Sartorius Stedim Biotech continues positive development and expands profitable growth

Sartorius Stedim Biotech reported 1H 2026 sales revenue of EUR 1,527m, up 6.4% in constant currencies including U.S. tariff refunds and customer surcharge compensation. Underlying EBITDA was EUR 479m (31.4% margin) and net profit EUR 181m. Management confirmed 2026 guidance for sales growth of 6% to 10% in constant currencies and EBITDA margin slightly above 31%.

Related tickers